: Regeneron gets FDA approval for Ebola drug

/ / News

Regeneron Pharmaceuticals Inc. REGN said late Wednesday the Food and Drug Administration approved its treatment for the Ebola virus. The biotech company said the agency approved Inmazeb, the first FDA-approved treatment for Ebola. In a 154-patient study of the drug, about 34% of Ebola patients died after 28 days, compared with 51% of patients who did not receive the drug, Regeneron said. The company received recent attention after President Donald Trump praised Regeneron’s experimental COVID-19 treatment that he received. Regeneron shares are up 60% for the year, compared with an 8% gain by the S&P 500 index SPX.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.